Novel Administration Routes, Delivery Vectors, and Application of Vaccines Based on Biotechnologies: A Review

Overview

Journal Vaccines (Basel)

Date 2024 Sep 28

PMID 39340032

Authors

Chung-I Rai

Tsu-Hsiang Kuo

Yuan-Chuan Chen

Affiliations

Soon will be listed here.

Abstract

Traditional vaccines can be classified into inactivated vaccines, live attenuated vaccines, and subunit vaccines given orally or via intramuscular (IM) injection or subcutaneous (SC) injection for the prevention of infectious diseases. Recently, recombinant protein vaccines, DNA vaccines, mRNA vaccines, and multiple/alternative administering route vaccines (e.g., microneedle or inhalation) have been developed to make vaccines more secure, effective, tolerable, and universal for the public. In addition to preventing infectious diseases, novel vaccines have currently been developed or are being developed to prevent or cure noninfectious diseases, including cancer. These vaccine platforms have been developed using various biotechnologies such as viral vectors, nanoparticles, mRNA, recombination DNA, subunit, novel adjuvants, and other vaccine delivery systems. In this review, we will explore the development of novel vaccines applying biotechnologies, such as vaccines based on novel administration routes, vaccines based on novel vectors, including viruses and nanoparticles, vaccines applied for cancer prevention, and therapeutic vaccines.

Citing Articles

Platform Technology in Global Vaccine Regulation: Development, Applications, and Regulatory Strategies with Insights from China.

Li X, Jin S, Guo S, Yang D, Sai W, Qiu X Vaccines (Basel). 2025; 12(12.

PMID: 39772096 PMC: 11728622. DOI: 10.3390/vaccines12121436.

References

Chauhan A, Agarwal A, Jaiswal N, Singh M . ChAdOx1 nCoV-19 vaccine for SARS-CoV-2. Lancet. 2020; 396(10261):1485-1486. PMC: 7832915. DOI: 10.1016/S0140-6736(20)32271-6. View

Schrauf S, Tschismarov R, Tauber E, Ramsauer K . Current Efforts in the Development of Vaccines for the Prevention of Zika and Chikungunya Virus Infections. Front Immunol. 2020; 11:592. PMC: 7179680. DOI: 10.3389/fimmu.2020.00592. View

Heida R, Hinrichs W, Frijlink H . Inhaled vaccine delivery in the combat against respiratory viruses: a 2021 overview of recent developments and implications for COVID-19. Expert Rev Vaccines. 2021; 21(7):957-974. DOI: 10.1080/14760584.2021.1903878. View

Tovar J, Bazaldua O, Vargas L, Reile E . Human papillomavirus, cervical cancer, and the vaccines. Postgrad Med. 2008; 120(2):79-84. DOI: 10.3810/pgm.2008.07.1794. View

Heida R, Frijlink H, Hinrichs W . Inhalation of vaccines and antiviral drugs to fight respiratory virus infections: reasons to prioritize the pulmonary route of administration. mBio. 2023; 14(5):e0129523. PMC: 10653782. DOI: 10.1128/mbio.01295-23. View

Shah N, Ghosh A, Kumar K, Dutta T, Mahajan M . A review of safety and immunogenicity of a novel measles, mumps, rubella (MMR) vaccine. Hum Vaccin Immunother. 2024; 20(1):2302685. PMC: 10798359. DOI: 10.1080/21645515.2024.2302685. View

Jose J, Khot K, Shastry P, Gopan G, Bandiwadekar A, Thomas S . Recent advancements in microneedle-based vaccine delivery. Int J Surg. 2022; 107:106973. DOI: 10.1016/j.ijsu.2022.106973. View

Bezbaruah R, Chavda V, Nongrang L, Alom S, Deka K, Kalita T . Nanoparticle-Based Delivery Systems for Vaccines. Vaccines (Basel). 2022; 10(11). PMC: 9694785. DOI: 10.3390/vaccines10111946. View

Carvalho M, Gill D . Rotavirus vaccine efficacy: current status and areas for improvement. Hum Vaccin Immunother. 2018; 15(6):1237-1250. PMC: 6663136. DOI: 10.1080/21645515.2018.1520583. View

10.

Iwata H, Kakita K, Imafuku K, Takashima S, Haga N, Yamaguchi Y . Safety and dose-sparing effect of Japanese encephalitis vaccine administered by microneedle patch in uninfected, healthy adults (MNA-J): a randomised, partly blinded, active-controlled, phase 1 trial. Lancet Microbe. 2022; 3(2):e96-e104. DOI: 10.1016/S2666-5247(21)00269-X. View

11.

Ramachandran S, Satapathy S, Dutta T . Delivery Strategies for mRNA Vaccines. Pharmaceut Med. 2022; 36(1):11-20. PMC: 8801198. DOI: 10.1007/s40290-021-00417-5. View

12.

Wang S, Liang B, Wang W, Li L, Feng N, Zhao Y . Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases. Signal Transduct Target Ther. 2023; 8(1):149. PMC: 10081433. DOI: 10.1038/s41392-023-01408-5. View

13.

Sadoff J, Gray G, Vandebosch A, Cardenas V, Shukarev G, Grinsztejn B . Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021; 384(23):2187-2201. PMC: 8220996. DOI: 10.1056/NEJMoa2101544. View

14.

DAlise A, Leoni G, Cotugno G, Siani L, Vitale R, Ruzza V . Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses. Clin Cancer Res. 2024; 30(11):2412-2423. PMC: 11145154. DOI: 10.1158/1078-0432.CCR-23-3940. View

15.

Zhao B, Jin Z, Yu Y, Li Y, Wang J, Wan W . A Thermostable Dissolving Microneedle Vaccine with Recombinant Protein of Botulinum Neurotoxin Serotype A. Toxins (Basel). 2022; 14(12). PMC: 9781108. DOI: 10.3390/toxins14120881. View

16.

Sfakianos J, Salome B, Daza J, Farkas A, Bhardwaj N, Horowitz A . Bacillus Calmette-Guerin (BCG): Its fight against pathogens and cancer. Urol Oncol. 2020; 39(2):121-129. DOI: 10.1016/j.urolonc.2020.09.031. View

17.

Schiller J, Lowy D . An Introduction to Virus Infections and Human Cancer. Recent Results Cancer Res. 2020; 217:1-11. PMC: 8336782. DOI: 10.1007/978-3-030-57362-1_1. View

18.

Bencina G, Oliver E, Meiwald A, Hughes R, Morais E, Weston G . Global burden and economic impact of vaccine-preventable cancer mortality. J Med Econ. 2024; 27(sup2):9-19. DOI: 10.1080/13696998.2024.2350877. View

19.

Shi L, Sings H, Bryan J, Wang B, Wang Y, Mach H . GARDASIL: prophylactic human papillomavirus vaccine development--from bench top to bed-side. Clin Pharmacol Ther. 2007; 81(2):259-64. DOI: 10.1038/sj.clpt.6100055. View

20.

Finn O, Forni G . Prophylactic cancer vaccines. Curr Opin Immunol. 2002; 14(2):172-7. DOI: 10.1016/s0952-7915(02)00317-5. View